GSK broadens drug-development partnership with NPS

08/2/2011 | Reuters

GlaxoSmithKline expanded a collaboration with NPS Pharmaceuticals to take over development and marketing of ronacaleret. The drug was designed to treat osteoporosis, but GSK will develop it as stem cell transplant therapy. The agreement also grants NPS development rights to SB-423557 and SB-423562 for autosomal dominant hypocalcemia with hypercalciuria.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL